

Articles

Association of Rare Genetic Variants in Opioid Receptors with Tourette Syndrome

Christel Depienne^{1,2*}, Sorana Ciura¹, Oriane Trouillard¹, Delphine Bouteiller¹, Elsa Leitão², Caroline Nava^{1,3}, Boris Keren³, Yannick Marie¹, Justine Guegan¹, Sylvie Forlani¹, Alexis Brice¹, Mathieu Anheim⁴, Yves Agid¹, Paul Krack^{5,6}, Philippe Damier⁷, François Viallet⁸, Jean-Luc Houeto⁹, Franck Durif¹⁰, Marie Vidailhet^{1,11}, Yulia Worbe^{1,11,12}, Emmanuel Roze^{1,12}, Edor Kabashi¹ & Andreas Hartmann^{1,11,12*}

¹INSERM, U 1127, CNRS UMR 7225, Faculté de Médecine de Sorbonne Université, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Hôpital Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013 Paris, FR, ²Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, DE, ³Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département de Génétique, 47-83 Boulevard de l'Hôpital, 75013 Paris, FR, ⁴Service de neurologie, CHU de Strasbourg, Hôpital de Hautepierre, Avenue Molière, 67200 Strasbourg Strasbourg, FR, ⁵Service de Neurologie, CHU de Grenoble, Avenue Maquis du Grésivaudan, 38700 La Tronche, FR, ⁶Center for Movement Disorders, Inselspital, University of Bern, Freiburgstrasse 18, 3010 Bern, Switzerland, ⁷Service de Neurologie, CHU de Nantes, 5 Allée de l'Île Gloriette, 44093 Nantes, FR, ⁸Service de Neurologie, CRHU d'Aix-en-Provence, Avenue des Tamaris, 13100 Aix-en-Provence, FR, ⁹Service de Neurologie, CHU de Poitiers, 2 Rue de la Milétrie, 86021 Poitiers, FR, ¹⁰Service de Neurologie, CHU de Clermont-Ferrand, CHU de Clermont-Ferrand, Hôpital Gabriel Montpied, 58 rue Montalembert, 63003 Clermont-Ferrand, FR, ¹¹Assistance Publique Hôpitaux de Paris (APHP), Hôpital Pitié-Salpêtrière, Département de Neurologie, 47-83 Boulevard de l'Hôpital, 75013 Paris, FR, ¹²AP-HP, Centre de Référence National Maladie Rare 'Syndrome Gilles de la Tourette', Hôpital Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013 Paris, FR

Abstract

Background: Genes involved in Tourette syndrome (TS) remain largely unknown. We aimed to identify genetic factors contributing to TS in a French cohort of 120 individuals using a combination of hypothesis-driven and exome-sequencing approaches.

Methods: We first sequenced exons of *SLITRK1-6* and *HDC* in the TS cohort and subsequently sequenced the exome of 12 individuals harboring rare variants in these genes to find additional rare variants contributing to the disorder under the hypothesis of oligogenic inheritance. We further screened three candidate genes (*OPRK1*, *PCDH10*, and *NTSR2*) preferentially expressed in the basal ganglia, and three additional genes involved in neurotensin and opioid signaling (*OPRM1*, *NTS*, and *NTSR1*), and compared variant frequencies in TS patients and 788 matched control individuals. We also investigated the impact of altering the expression of *Oprk1* in zebrafish.

Results: Thirteen ultrarare missense variants of *SLITRK1-6* and *HDC* were identified in 12 patients. Exome sequencing in these patients revealed rare possibly deleterious variants in 3,041 genes, 54 of which were preferentially expressed in the basal ganglia. Comparison of variant frequencies altering selected candidate genes in TS and control individuals revealed an excess of potentially disrupting variants in *OPRK1*, encoding the opioid kappa receptor, in TS patients. Accordingly, we show that downregulation of the *Oprk1* orthologue in zebrafish induces a hyperkinetic phenotype in early development.

Discussion: These results support a heterogeneous and complex genetic etiology of TS, possibly involving rare variants altering the opioid pathway in some individuals, which could represent a novel therapeutic target in this disorder.

Keywords: Tourette syndrome, gene, variant, susceptibility factor, opioid receptor, zebrafish, *OPRK1*

Citation: Depienne C, Ciura S, Trouillard O, Bouteiller D, Leitão E, Nava C, Keren B, Marie Y, Guegan J, Forlani S, Brice A, Anheim M, Agid Y, Krack P, Damier P, Viallet F, Houeto JL, Durif F, Vidailhet M, Worbe Y, Roze E, Kabashi E, Hartmann A. Association of Rare Genetic Variants in Opioid Receptors with Tourette Syndrome. Tremor Other Hyperkinet Mov. 2019; 9. doi: 10.7916/tohm.v0.693

*To whom correspondence should be addressed. E-mail: christel.depienne@uni-due.de or andreas.hartmann@aphp.fr

Editor: Elan D. Louis, Yale University, USA

Received: June 25, 2019; **Accepted:** October 15, 2019; **Published:** November 22, 2019

Copyright: © 2019 Depienne et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.

Funding: This study was financially supported by the Association Française du Syndrome Gilles de la Tourette (AFSGT), Merz-Pharma, ICM, and INSERM. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this article were obtained from the GTEx Portal on 09/13/2017.

Financial Disclosures: None.

Conflicts of Interest: The authors report no conflict of interest.

Ethics Statement: This study was performed in accordance with the ethical standards detailed in the Declaration of Helsinki. The authors' institutional ethics committee has approved this study and all patients have provided written informed consent.

Data Availability: Individuals included in this study have not consented to have their exome data released. The raw data that support the findings of this study, with the exception of individual exome data, are available from the corresponding authors, upon request.

Supplementary material: To access the supplementary material, please visit the article landing page.

Introduction

Tourette syndrome (TS) is a neurodevelopmental disorder characterized by multiple involuntary motor and vocal tics that typically begin in childhood and have a waxing and waning course.^{1–3} Twin studies have provided compelling evidence that TS is genetically determined,^{4–7} but the nature of the involved genetic factors, their mode of inheritance, and the mechanisms by which they act remain largely unknown.

Recent studies have emphasized that the genetic architecture of TS is very likely oligo- (i.e., involving a few gene loci) or poly-genic (i.e., influenced by many genes as well as environmental factors) and overlaps with that of frequently comorbid disorders, such as autism spectrum disorders, obsessive-compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), and depression.^{8–10} Main genes possibly involved in TS so far include *NRXN1*, *CNTN6*, *CELSR3*, *SLITRK1*, and *HDC*.^{11–22} *SLITRK1* encodes a transmembrane protein modulating neurite outgrowth belonging to a family comprising six paralogues (*SLITRK1* to *SLITRK6*) in mammals.^{23,24} *HDC* encodes histidine decarboxylase, the enzyme catalyzing the synthesis of histamine through decarboxylation of histidine.¹¹ *Sltk1*-, *Sltk5*-, and *Hdc*-deficient mice show behavioral disturbances and elevated anxiety-like behaviors, further supporting the involvement of these genes in neuropsychiatric disorders.^{25–31}

In this study, we sequenced exons of *SLITRK1-6* and *HDC* genes and analyzed the exome of 12 TS patients with rare variants in these genes to find additional hits contributing to the disorder under the hypothesis of oligogenic inheritance. We focused our analysis on rare, possibly disrupting variants in genes preferentially expressed in the basal ganglia, one of the main brain regions of interest in TS.³² Screening of candidate genes in our TS cohort and comparison of variant frequencies in control populations identified *OPRK1* variants as susceptibility factors for TS.

Methods

Participants

This study included 120 French individuals (92 males and 28 females, M/F sex ratio: 3.3) with TS syndrome recruited from the “Réseau National Gilles de la Tourette” (INSERM RBM 04-18; 2005–2007) and the “Centre de Référence National Maladies Rares Syndrome Gilles de la Tourette” (Pitié-Salpêtrière Hospital, Paris, France). Patient assessment is described in detail elsewhere.³³ Twelve patients with rare variants in *SLITRK1-6* and *HDC* (see supplementary Table 1) from this cohort were identified and further analyzed by exome sequencing (Figure 1). One patient out of 12 (SGT-003-04) had pervasive developmental disorder not otherwise specified (PDD-NOS) in addition to TS. A total of 788 French healthy individuals matched on sex (632 males and 156 females, M/F sex ratio: 4.0) were selected from the same data-bank (DNA and cell bank of Institut du Cerveau et de la Moelle épinière [ICM]) to compare variant frequencies in *NTS*, *OPRK1*, and *OPRM1*. Genomic DNA was extracted from blood cells using standard phenol–chloroform procedures.

Sanger sequencing

Specific primer pairs were designed to amplify the coding exons and adjacent intron–exon boundaries of *SLITRK1-6* and *HDC*.




Figure 1. Flowchart Illustrating the Strategy and Results of this Study. The scheme summarized the different experimental steps and main results obtained.

The same primers were used to sequence the coding regions of these genes in the 120 TS patients. After exome sequencing, six genes were selected and sequenced by Sanger sequencing: *OPRK1*, *OPRM1*, *PCDH10*, *NTS*, *NTSR1*, and *NTSR2*. All primer sequences are provided in supplementary Table 2. Forward and reverse sequence reactions were performed with the Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA). G50-purified sequence products were run on an ABI 3730 automated sequencer (PE Applied Biosystems) and data were analyzed with Seqscape v2.6 software (Applied Biosystems). In addition, 63 variants identified by exome sequencing were confirmed by Sanger sequencing (supplementary Table 3). For genes with multiple expressed isoforms, the longest isoform was used to describe variants. The variant nomenclature is based on the following cDNA reference sequences: *OPRM1*: NM_001145279 (longest isoform) and NM_000914.4 (main isoform); *OPRK1*: NM_000912.3; *PCDH10*: NM_032961.1; *NTS*: NM_006183.4; *NTSR1*: NM_002531.2; *NTSR2*: NM_012344.3.

Exome sequencing

We sequenced the exome of 12 patients with variants in *SLITRK1-6* and *HDC* (Figure 1). Genomic DNA was captured using the SureSelect Human All Exon 50 Mb Kit (Agilent, Santa Clara, CA, USA) followed by paired-end 75 bp massively parallel sequencing on a HiSeq2000-sequencing system (Illumina, San Diego, CA), according to the manufacturer's instruction and protocols,³⁴ by Integragen SA (Evry, France). Image analysis and base calling were performed using Illumina Real Time Analysis (RTA) Pipeline version 1.8 with default parameters. Analysis of exome data was based on the Illumina CASAVA1.7 pipeline, using the ELANDv2 alignment algorithm. Variant annotation was realized with an in-house pipeline (Integragen Evry, France), consisting of gene annotation (RefSeq), frequencies of the variants at the homozygous or heterozygous state in databases (HapMap, 1,000 genomes, exome variant server [EVS]) and in exomes sequenced at Integragen, and analysis of the impact of the variants (exonic, intronic, silent, nonsense, etc.). Variant filtering was performed using the Eris interface (Integragen) with the following parameters: (1) minor allele frequencies (MAFs) ≤ 0.01 (rare heterozygous variants) or 0.001 (homozygous variants) in dbSNP, Hapmap, 1,000 genomes, AVS, and a local exome database; (2) a predictable damaging impact on the gene or the protein (nonsense variants, variants predicted to cause a frameshift, variants altering splice sites, missense variants, and variants introducing in-frame deletions or insertions); (3) coverage ≥ 10 reads and exclusion of ambiguous genotypes (supplementary Table 3). This list was then filtered to keep genes with variants (same or different) in at least two TS patients (supplementary Table 4). These parameters allowed to detect all 13 variants previously identified in the *HDC* and *SLITRK1-6* genes. For six patients, DNA from both parents was available and their exome was also sequenced to investigate *de novo* variants. For one family (SGT-003), parents were included in the first analysis. For the five remaining families, the index case and the parents were resequenced independently and these data were used to validate variants identified in the first experiment. Exome sequencing in family SGT-082 revealed an unexplained incompatibility of the paternal DNA.

Microarrays

Copy number variants (CNVs) were independently assessed in 11/12 index cases with *HDC* and *SLITRK1-6* variants using OmniExpress24 microarrays (Illumina). Automated Illumina microarray experiments were performed according to the manufacturer's specifications. Image acquisition was performed using an iScan System (Illumina, San Diego, CA, USA). Image analysis and automated CNV calling were performed using GenomeStudio v2011.1 and CNVPartition v3.1.6 with the default confidence threshold of 35. CNVs identified in TS patients were compared to those present in the Database of Genomic Variants (DGV), using Cartagenia Bench (Agilent). Variants absent from DGV, present in less than three individuals, or with an overlap $<80\%$ with CNVs present in DGV were listed (supplementary Table 5).

Pyrosequencing

To compare the frequencies of rare variants in *NTS*, *OPRM1*, and *OPRK1*, exons and intron-exon junctions of these genes were screened

in 120 patients with TS and 788 healthy controls using amplicon-based massive parallel pyrosequencing with a Roche 454 GS Junior. A first polymerase chain reaction (PCR) was performed to amplify the targeted exons by PCR (primers in supplementary Table 2). A second PCR was performed to incorporate multiplex identifier and 454 adaptors, and an emulsion PCR was carried out according to the emPCR Amplification Method Manual (Roche, Basel, Switzerland). All variants previously identified by Sanger sequencing were also detected by pyrosequencing in the TS cohort.

Bioinformatic analyses

Variants identified in TS individuals were annotated using Alamut 2.7.1 (Interactive Biosoftware, Rouen, France). This software allows automatic gene variant annotation including missense predictions using Align GVGD, SIFT, Mutation Taster and Polyphen-2. Rare variants correspond to variant with $MAF < 0.01$; ultrarare variants have an $MAF < 0.001$. We used the statistical overrepresentation tests from PANTHER 14.1³⁵ with the "GO biological process complete" option to look for molecular pathways and functions enriched in gene lists with rare variants identified by exome sequencing in TS patients (supplementary Tables 6 and 7).

Median Reads Per Kilobase Million (RPKM) values for each human gene GTEx Analysis V6p were downloaded from the Genotype-Tissue Expression (GTEx) portal (<https://www.gtexportal.org/>). Genes preferentially expressed in the adult basal ganglia or substantia nigra (maximum RPKM value in caudate, nucleus accumbens, putamen, or substantia nigra > maximum RPKM value in other tissues/brain regions) were listed and ranked according to their expression in basal ganglia/substantia nigra compared to other tissues. The final list includes 491 transcripts with $RPKM > 0.5$ (supplementary Table 8). We then listed the 64 variants present in the 12 individuals in basal ganglia-enriched genes (supplementary Table 9). Gene annotation (gene function, gene expression, related phenotypes, or disorders in mice and humans) was performed using GeneALaCarte (<http://www.genecards.org/cgi-bin/BatchQueries/Batch.pl>) and MGI Batch Query (<http://www.informatics.jax.org/batch>).

Missense and Loss-of-function (LoF) variants present in *PCDH10*, *NTS*, *NTSR1*, *NTSR2*, *OPRK1*, and *OPRM1* present in the gnomAD³⁶ r2.0.1 database (<http://gnomad.broadinstitute.org/>) were downloaded. *In silico* pathogenicity predictions calculated by PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) were systematically retrieved for missense variants present in gnomAD using the batch query tool (<http://genetics.bwh.harvard.edu/pph2/bgi.shtml>). Possibly or probably damaging predictions by Polyphen-2, which usually are the most stringent of all four predictions tools, were used to filter possibly damaging variants and compare variant frequencies (supplementary Table 11). Variant frequencies were compared using exact Fisher's tests.

Zebrafish studies

Adult and larval zebrafish (*Danio rerio*) were maintained in the animal platform of Inserm Unit U1127, ICM in Paris, according to the National and European Guidelines for Animal Welfare. Experiments

were performed on wild type embryos from AB and TL strains. Zebrafish larvae were raised in embryo water: 0.6 g/L aquarium salt (Instant Ocean, Blacksburg, VA) in reverse osmosis water + 0.01 mg/L methylene blue in a 28°C incubator. Microinjections of 0.5 nL of solution were carried out at one-cell stage of zebrafish embryos. Antisense Morpholino oligonucleotides (AMOs) (GeneTools Philomath, OR) were used to knock down the expression of the sole orthologue of the opioid receptor kappa 1 (*Oprk1*: NM_182886) gene in zebrafish. The sequence of the ATG-targeting AMO was the following AAATCTGCACCACGTTGCTGTCCA that would bind to the following genomic sequence in the zebrafish genome: ACAGGCATCACTATTGTTTTCAAACCTTG-GGATTTTCGTCTTAACTACCTGTTTAAAATTACACAACAAGACG[(ATG)GACAGCAACGTGGTGCAGATTT]. The mismatch control for this AMO was the following (small letters scrambled to disrupt binding) AAATaTGaACCACaTTGCTaTcCaA. To ensure the AMO specificity, we also utilized a splice AMO targeting the exon2–intron2 junction with the following sequence: AGGACAATGCTGTTTCTTACCTGAT. Mismatch control for the splice AMO was the following: AGcACAATcTcTTTCTTACgTcAT. All AMOs were used at a concentration of 0.6 mM in the injection solution for a total amount of 2.5 ng of AMO injected per egg. For rescue experiments, the human wild-type *OPRK1* cDNA construct was obtained from Dharmacon, Lafayette, CO, USA, cloned into a pCS2 plasmid, and injected alongside the AMO at a concentration of 75 ng/μL. Total RNA from embryos was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA). RNA was quantified using the Nanodrop 8000 (Thermo Scientific, Waltham, MA). cDNA was synthesized using Transcriptor Universal cDNA Master Mix (Roche) with the following primer pairs to detect the expression and splicing of the *OPRK1* transcript: forward: 5'-CATCACTGCCGTTTACTCCGT and reverse 5'-TCATTGGTGTCGGAAGTCC. To record global activity, 28 hpf zebrafish embryos in their chorion were placed on a plastic mesh, submerged in embryo water, and imaged at the frequency of 30 fps as previously described.³⁷ Activity parameters were quantified using an automatized Zebrolab system (ViewPoint, France). Analysis of variance (ANOVA) was performed using the SigmaStat software (California) and data were reported as significant when $p < 0.05$.

Results

To study the contribution of variants in *HDC* and *SLITRK* genes in the French TS cohort, coding exons of *SLITRK1*, *SLITRK5*, *SLITRK6* (chromosome [chr] 13), *SLITRK3* (chr3), *SLITRK2*, *SLITRK4* (chrX), and *HDC* (chr15) were screened in 120 TS patients by Sanger sequencing (Figure 1). Seventeen rare heterozygous variants (MAF < 0.01) were identified in 19 unrelated index probands (supplementary Table 1). Among these, 12 individuals carried 13 ultrarare (MAF < 0.001) variants modifying the coding sequence (supplementary Table 1, supplementary Figure 1). All variants but one (*HDC*: c.1492A>G, p.Arg498Gly), which was present in an individual who also had a variant in *SLITRK6* (c.1232C>G, p.Thr411Arg), alter amino acids conserved in mammals (supplementary Figure 2). One of the three *SLITRK1* variants (c.1252A>T, p.Thr418Ser) was previously described in patients with OCD.³⁸

Seven variants for which inheritance could be assessed were inherited from asymptomatic parents, indicating that these variants, if involved in the etiology of TS, are insufficient on their own to lead to the disorder.

To find additional hits contributing to the disorders under the assumption of oligogenic inheritance, we sequenced the exome of these 12 patients (Figure 1). We identified a total of 3,755 rare variants (mean number of variants = 408 per patient; range: 342–595) altering coding sequences or splice sites in 3,041 genes (supplementary Table 3). A set of 63 variants in selected candidate genes was validated by Sanger sequencing in the affected subjects, confirming the presence of all variants but one (supplementary Table 3). At least two different variants were identified in two or more individuals in 424 genes (supplementary Table 4). One individual (SGT-040-10) for whom DNA from both parents was available had two *de novo* variants absent or present at a very low frequency in gnomAD: a *de novo* duplication (arr[hg19] 17q12(37,042,006–37,276,683) × 3) on chr 17q12 including three genes (*FBXO47*, *LASPI*, *PLXDC1*) and a *de novo* missense variant (NM_005739.3: c.2327T>C, p.Ile776Thr) in the *RASGRP1* gene (supplementary Table 5).

We used PANTHER to determine whether specific biological processes were enriched in the 3,041 and 424 gene lists, respectively. Interestingly, both lists were enriched in genes involved in cell differentiation, cell adhesion, cell projection organization, neurogenesis, and neuron differentiation among other cellular processes (supplementary Tables 6 and 7). Genes involved in these pathways include *NRP2* (three individuals), *ROBO4* (two individuals), *SLIT2*, *NTN5*, *RELN*, *RGMA*, plexins (*PLXNA1*, *PLXNB1*), semaphorins (*SEMA4F*, *SEMA6B*: two individuals each, *SEMA3B*, *SEMA3C*, *SEMA4B*, *SEMA5A*, *SEMA5B*, *SEMA6D*), ephrins (*EPHA1*, *EPHA6*: two individuals each, *EPHA8*, *EPHA10*, *EPHB4*), cadherins (*CDH4*: three individuals, *CDH20*), protocadherins (*PCDH10*), cadherin EGF LAG Seven-Pass G-type receptors (*CELSR3*: two individuals; *CELSR2*), and fat-like cadherins (*FAT4*: four individuals; *FAT3*: three individuals; *FAT1*: two individuals; *FAT2*).

We then examined variants in genes preferentially expressed in the basal ganglia (supplementary Table 8), corresponding to a total of 64 variants in 54 genes (supplementary Table 9). Among these variants, two in *PCDH10*/protocadherin 10 (c.3076C>T; p.Arg1026*) and *OPRK1*/opioid receptor kappa-1 (c.787C>T; p.Arg263*) lead to a theoretical protein truncation. A missense variant in the neurotensin receptor-2 (*NTSR2*, c.397C>G, p.Arg133Gly) altering a highly conserved amino acid (until *C. elegans*) was predicted to be damaging by all four prediction tools used.

Opioid and neurotensin signaling pathways being relevant to TS etiology, we examined variants in genes encoding ligand or receptors independently of their preferential expression in the brain. We observed rare variants possibly altering other genes involved in opioid (c.743C>T, p.Thr248Ile in *OPRM1*/opioid receptor Mu-1) and neurotensin (c.423G>C, p.Lys141Asn in *NTS*/neurotensin, and c.533C>T, p.Thr178Ile in *NTSR1*/neurotensin receptor-1) pathways in three additional patients.

We then screened *NTS*, *NTSR1*, *NTSR2*, *OPRK1*, *OPRM1*, and *PCDH10* by Sanger sequencing for additional variants in our TS cohort. Additional rare variants were identified in all six genes, including

PCDH10 missense variants (c.1526G>A, p.Gly509Asp and c.2411T>C, p.Ile804Thr) in three individuals, one frameshift (c.348del, p.Gln117Asnfs*5) and one missense variant (c.190C>A, p.Leu64Ile) in *NTS* in two individuals, rare variants in *NTSR1* and *NTSR2* in 11 and 3 individuals each, one nonsense (c.1107C>A, p.Tyr369*) and three missense variants in *OPRK1* (four individuals), and eight rare variants including a nonsense variant (c.829C>T, p.Arg277*) in *OPRM1* (supplementary Table 10).

Comparison of rare variant frequencies between TS cases and individuals from the gnomAD database suggested that variants in *OPRK1* may be more frequent in TS patients than in control individuals (TS: 4.2%, controls: 0.8%; $p = 0.003$, Fisher's exact test, Table 1, supplementary Tables 10 and 11). To further confirm these findings, we reanalyzed TS cases and a control population comprising 788 individuals matched on sex from the same databank for variants in *OPRK1* using pyrosequencing (supplementary Table 10). We also included *NTS* and *OPRM1* in this screening based on the identification of truncating variants in these genes. Comparison of variant frequencies in TS cases and matched controls confirmed that there was a significant excess of rare variants in *OPRK1* (TS: 4.2%, controls: 0.5%; $p = 0.003$, Fisher's exact test), and to a lesser extent in *OPRM1* (TS: 6.7%, controls: 2.3%; $p = 0.048$, Fisher's exact test) in TS patients, while the difference for *NTS* (TS: 2.5%, controls: 1.2%; $p = 0.397$, Fisher's exact test) was not significant (Table 1). Variants of *OPRK1* and *OPRM1* in which inheritance could be assessed were all inherited from an asymptomatic parent. In two families including affected siblings, the variant was also present in the affected sib (supplementary Table 3, supplementary Figure 3). These results suggest that variants in opioid receptors could represent susceptibility factors to TS.

We next tested the functional consequences of altering the expression of the TS candidate orthologous genes during vertebrate development. For this, we focused on the expression of *oprk1* in zebrafish, a simple vertebrate model that exhibits stereotyped movements during early development.³⁹ The zebrafish genome contains a single orthologue of the human *OPRK1* gene (ensembl: *oprk1* ENSDARG00000006894) with 67% identity at the protein level. *Oprk1* expression is enriched in brain structures of the diencephalon and mesencephalon in adult zebrafish,⁴⁰ and is expressed during the development of the embryo.⁴¹ To investigate the function of *Oprk1* during early development, we performed a knock-down of its expression via microinjections of morpholino-modified antisense oligonucleotides (AMO) in the one-cell stage embryo. We used two different strategies to knock down the expression of *oprk1*, targeting either the ATG starting codon or the splice junction exons 2/intron 2. Injection of 2.5 ng of either AMOs did not result in gross morphological defects at 28 hpf (Figure 2A) or at later stages of development (not shown) when compared with non-injected or with mismatch AMO-injected controls. To determine the effectiveness of the splice-modifying AMO, we performed reverse transcription PCR using primers flanking the exon 2–exon 3 junction. Microfluidic capillary electrophoresis of the PCR products revealed a defective splicing event in fish injected with the splice-blocking AMO (Figure 2B). Further, a lower amount of PCR product was detected in the ATG-targeting AMO injected fish, indicating a degradation of the *oprk1* transcript (Figure 2B).

To determine the effect of *oprk1* knockdown on the motor activity, we analyzed the movement of zebrafish embryos at 28 hpf. This developmental stage marks the appearance of the first stereotyped movement, consisting of bidirectional periodic coils inside the chorion.

Table 1. Comparison of the Frequencies of Rare Variants in Six Selected Genes in TS and Control Populations

Gene	Type of variants	TS cohort (120 individuals)	gnomAD (138,632 individuals)	p	Control individuals (788 individuals)	p
<i>OPRK1</i> *	Missense/LoF (MAF<1%)	5 (4.2%)	1099 (0.8%)	0.003	4 (0.5%)	0.003
	Damaging/LoF (MAF<1%)	4 (3.3%)	541 (0.4%)	0.001	3 (0.4%)	0.007
<i>OPRM1</i> **	Missense/LoF (MAF<1%)	8 (6.7%)	8,085 (5.8%)	0.694	22 (2.3%)	0.048
	Damaging/LoF (MAF<1%)	5 (4.2%)	3,786 (2.7%)	0.268	10 (1.2%)	0.037
<i>NTS</i>	Missense/LoF (MAF<1%)	3 (2.5%)	998 (0.7%)	0.057	10 (1.2%)	0.397
	Damaging/LoF (MAF<1%)	2 (1.7%)	474 (0.3%)	0.064	2 (0.25%)	0.087
<i>NTSR1</i>	Missense/LoF (MAF<1%)	12 (10.0%)	14,333 (10.3%)	1.000	ND	
	Damaging/LoF (MAF<1%)	6 (5.0%)	8,248 (5.9%)	0.847	ND	
<i>NTSR2</i>	Missense/LoF (MAF<1%)	4 (3.3%)	3,142 (2.3%)	0.353	ND	
	Damaging/LoF (MAF<1%)	4 (3.3%)	1,772 (1.3%)	0.069	ND	
<i>PCDH10</i>	Missense/LoF (MAF<1%)	4 (3.3%)	2,494 (1.8%)	0.171	ND	
	Damaging/LoF (MAF<1%)	3 (2.5%)	1,174 (0.8%)	0.083	ND	

The details of variants included in the comparisons appear in supplementary Tables 10 and 11. The number of variants/individuals calculated from gnomAD (supplementary Table 11) assumed that rare variants correspond to one individual each. Variant frequencies were compared with Fisher's exact tests. * Calculations for *OPRK1* excluded Asp374Asp, which is frequent in the African population (longest isoform NM_001318497). ** For *OPRM1*, only variants in exons 3, 4, and 5 of isoform NM_001145279, which are present in at least 11/19 isoforms, were taken into account.




Figure 2. Knockdown of the Zebrafish OPRK1 Orthologue Results in Hyperactivity during Development. (A) Activity heatmap illustrating spontaneous movement of 28 hpf embryos inside the chorion during a 10 seconds period. Higher levels of activity are evident in embryos injected with *oprk1* splice-blocking AMO (spOPRK1) or ATG-targeting AMO (OPRK1 KD) when compared to mismatch AMO-injected embryos (Mismatch control). Expression of human *OPRK1* transcript (hOPRK1) rescues the hyperactivity phenotype. (B) RT-PCR product of amplification of a region spanning exons 2 and 3 of the zebrafish *oprk1* transcript. Injection of the splice-blocking AMO (spOPRK1) results in a defective splicing in this region. (C) Quantification of the total activity of 28 hpf zebrafish embryos. (D) Quantification of the frequency of movement bursts in the 28 hpf embryos.

We quantified this type of movement using an automated video capture and analysis system. As illustrated in Figure 2A, knockdown of *oprk1* was associated with an overall increase in activity in zebrafish. Indeed, injection of either the ATG-targeting or the splice blocking AMO resulted in significantly higher total movement (Figure 2C) and frequency of coiling bursts (Figure 2D). To confirm that the hyperkinetic phenotype is specifically associated with a loss of function of *oprk1*, we coexpressed human *OPRK1* together with the ATG-blocking AMO. As shown in Figure 2, overexpression of *OPRK1* functionally rescued the knockdown of the zebrafish orthologue, as both the total activity (Figure 2C) and the frequency of coiling movements (Figure 2D) were restored to control levels. Investigation of the global activity of zebrafish at later stages of development (48 hpf–5 dpf) revealed a gradual disappearance of the hyperactivity phenotype, with no significant differences from controls (not shown). Thus, in zebrafish, we observed an association of *oprk1* loss of function with a transient hyperkinetic phenotype at early stages of development.

Discussion

Genetics of TS is both complex and heterogeneous, making the identification of interacting variants extremely challenging. In an attempt to circumvent this difficulty, we focused on candidate genes enriched in brain structures relevant to TS pathophysiology, that is, the basal ganglia. Although straightforward, this approach would miss variants in genes potentially involved in TS-related networks dysfunction but rather mainly expressed in other brain regions or tissues.

The main finding of this study is an excess of possibly disrupting variants in *OPRK1*, the gene encoding the kappa opioid receptor (KOR) in patients with TS. We also detected a possible, weaker association of TS with rare variants in *OPRM1*, although these results have to be interpreted with caution, notably because *OPRM1* is a very polymorphic gene, encoding many different isoforms. We also show that knockdown

of the *oprk1* orthologue in zebrafish is associated with a hyperkinetic phenotype that is confined to the early stages of development. Overexpression of the human *OPRK1* transcript was able to rescue the loss of function of the zebrafish orthologue, highlighting the high functional conservation of the opioid receptor kappa during evolution and the relevance of its investigation in lower vertebrates. Altogether, these results further support the hypothesis that alteration of opioid receptor kappa *in vivo* could lead to an early transient hyperactivity phenotype mimicking TS. Extending this study to the functional analysis of variants identified in TS patients may also provide additional support for the potential role of *OPRK1* in TS pathogenesis.

The endogenous opioid system is composed of three different opioid receptor subtypes (mu, kappa, and delta), which have different function and brain distribution.⁴² These receptors are activated upon binding with endogenous peptides including dynorphins, enkephalins, endorphins, endomorphins and nociceptin, or exogenous drugs such as morphine or heroin. The opioid endogenous system, and more specifically the KOR system,⁴³ is involved in both motor control and psychiatric conditions such as anxiety, depression, schizophrenia, and addiction.⁴⁴ Sex differences in KOR function⁴⁵ might contribute to sex-dependent clinical manifestations or to imbalanced sex ratios existing in TS and many other neuropsychiatric conditions such as susceptibility to develop addictions and depression.

The implication of the opioid system in pathophysiology of TS has been hypothesized for more than 30 years, first based on treatment studies using opiate agonists and/or antagonists.^{46–50} Importantly, a post-mortem report of a single patient with TS showed total absence of dynorphin-like staining in the dorsal part of the globus pallidus externus and very faint staining in the ventral pallidum.⁵¹ This case was particularly interesting since it pinpointed toward underactivity of a specific opioid system, the dynorphin/kappa receptor system. Very recently and in line with our own findings, downregulation of *OPRK1* and *OPRM1*

opioid receptor gene expression in the postmortem striatum of nine patients with TS was reported.⁵² Frequent variants in *OPRK1* (rs702764) and *OPRM1* (rs1799971) have also recently been associated with impulse control disorders in Parkinson disease,^{53,54} a finding in agreement with genetic variants in opioid receptor contributing to impulsivity disorders, a comorbidity frequently associated with TS.⁵⁵

With relevance to TS, KORs are located on dopaminergic afferents where they reduce release and increase the reuptake of dopamine,⁵⁶ implying that inactivation of KORs (by *OPRK1* variants, for instance) may increase cerebral dopamine release, especially in regions such as the striatum.⁵⁷ This would be in line with the predominant theory that TS pathophysiology is associated with a dopaminergic hyperinnervation.⁵⁸ Little is known about the specific function of *oprk1* during zebrafish development; however, a role in the differentiation of Pax2-positive neurons has been suggested,⁴¹ with implications for the correct specification of the dopaminergic system.

Contrary to *Oprk1* knockdown in zebrafish, *Oprk1*-deficient mice did not show evidence of hyperactivity.⁵⁹ *Oprk1* knockdown in zebrafish and *Oprk1* knockout in mice cannot be strictly compared as compensation mechanisms are very likely different when *Oprk1* is downregulated or completely absent during development in these distinct species. Furthermore, locomotor activity is usually tested in adult mice and an early transient hyperactive phenotype could have been easily missed. Furthermore, locomotor phenotypes and behaviors also depend on the genetic background, as observed for *Oprk1*-deficient mice, which mainly showed impulsivity on a C57Bl/6J background.^{60,61} However, a recent study has shown that triple knockout of all three opioid receptors in mice is associated with hyperactivity (motor restlessness) and dopamine abnormalities.⁶²

The number of patients with opioid receptor variants in our TS cohort remains low (3.3–4.2% compared to 0.5–0.8% in control individuals). It is also important to note that a series of 120 individuals is small for case-control association studies, and that TS and control populations have not been matched for ancestry based on genotypes. Therefore, it would be important to replicate these findings in larger TS and control cohorts. The impact of population stratification on frequencies of variants in opioid receptors is illustrated by the *OPRM1* NM_001145279:c.397A>G, p.Asn133Asp (NM_000914.4:c.118A>G, p.Asn40Asp, rs1799971) variant, a common functional polymorphism that was shown to act as a susceptibility factor for addiction and to alter the response treatments targeting opioid receptors.⁶³ This variant was identified in 31 TS patients (28 heterozygotes and 3 homozygotes), a distribution similar to that observed in our control population as well as in the European (non-Finnish) population of gnomAD, suggesting that this polymorphism does not play a major role in TS etiology. However, we observed that the frequency of the G minor allele significantly varies across populations (much higher in Asian populations while lower in Africans; supplementary Table 12). This finding might have important consequences when considering opioid receptors as possible therapeutic targets in TS or other psychiatric disorders.

KOR agonists – assuming that residual receptor function is maintained – might indeed be novel therapeutic options to be investigated

in TS. However, classic KOR agonists such as U50,488 or U69,593 used experimentally to treat drug addiction have shown dysphoric and psychomimetic properties. Therefore, novel molecules based on Salvinorin A, the active compound of *Salvia divinorum*, are currently being developed for the treatment of substance abuse (particularly cocaine) but might also prove to be useful for the treatment of tics.⁶⁴

Finally, this work has also identified rare variants in several individuals in additional candidate genes including *PCDH10*, encoding a protocadherin with preferential expression in basal ganglia, possibly contributing to the establishment of synaptic connections in this brain region; *ROBO4*, a gene of the ROBO/SLIT axon guidance pathway previously associated with TS⁶⁵; *NRP2*, encoding neuropilin 2, a protein possibly controlling axon guidance of dopaminergic neurons⁶⁶; *NOS1*, encoding the neuronal nitric oxide synthase, a gene also downregulated in the striatum of TS patients⁵² and possibly playing a role in controlling motor behavior;⁶⁷ and *SHANK1*, in which truncating variants were previously associated with male-limited Asperger syndrome.⁶⁸ Two individuals also had variants in *CELSR3*, a gene that was recently recognized as a candidate gene for TS.²² The possible contribution of these genes to TS etiology needs to be confirmed in further studies, as are the nature and number of the variants acting in concert necessary to lead to TS.

Acknowledgments

The authors thank the patients for their participation in the study and the DNA and cell bank of ICM for DNA extraction and sample management.

References

1. Jankovic J. Tourette's syndrome. *New Engl J Med* 2001;345:1184–1192. doi: 10.1056/NEJMra010032
2. Hartmann A, Worbe Y. Tourette syndrome: clinical spectrum, mechanisms and personalized treatments. *Current Opin Neurol* 2018;31:504–509. doi: 10.1097/WCO.0000000000000575
3. Robertson MM, Eapen V, Singer H S, Martino D, Scharf J M, Paschou P, et al. Gilles de la Tourette syndrome. *Nat Rev Dis Primers* 2017;3:16097. doi: 10.1038/nrdp.2016.97
4. Comings DE, Comings BG, Devor EJ, Cloninger CR. Detection of major gene for Gilles de la Tourette syndrome. *Am J Hum Genet* 1984;36:586–600.
5. Price RA, Kidd KK, Cohen DJ, Pauls DL, Leckman JF. A twin study of Tourette syndrome. *Arch Gen Psychiatr* 1985;42:815–820. doi: 10.1001/archpsyc.1985.01790310077011
6. Price RA, Pauls DL, Kruger SD, Caine ED. Family data support a dominant major gene for Tourette syndrome. *Psychiatr Res* 1988;24:251–261. doi: 10.1016/0165-1781(88)90107-2
7. Pauls DL, Fernandez TV, Mathews CA, State MW, Scharf JM. The inheritance of Tourette disorder: a review. *J Obsessive Compuls Relat Disord* 2014;3:380–385. doi: 10.1016/j.jocrd.2014.06.003
8. Brainstorm C, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, et al. Analysis of shared heritability in common disorders of the brain. *Science* 2018;360:eaap8757. doi: 10.1126/science.aap8757

9. Clarke RA, Lee S, Eapen V. Pathogenetic model for Tourette syndrome delineates overlap with related neurodevelopmental disorders including Autism. *Transl Psychiatry* 2012;2:e158. doi: 10.1038/tp.2012.75
10. Hirschtritt ME, Darrow SM, Illmann C, Osiecki L, Grados M, Sandor P, et al. Genetic and phenotypic overlap of specific obsessive-compulsive and attention-deficit/hyperactive subtypes with Tourette syndrome. *Psychol Med* 2018;48(2):279–293. doi: 10.1017/S0033291717001672
11. Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, O’Roak BJ, Mason CE, et al. L-histidine decarboxylase and Tourette’s syndrome. *New Engl J Med* 2010;362:1901–1908. doi: 10.1056/NEJMoa0907006
12. Abelson JF, Kwan KY, O’Roak BJ, Baek DY, Stillman AA, Morgan TM, et al. Sequence variants in *SLITRK1* are associated with Tourette’s syndrome. *Science* 2005;310:317–320. doi: 10.1126/science.1116502
13. Willsey AJ, Fernandez TV, Yu D, King RA, Dietrich A, Xing J, et al. De Novo coding variants are strongly associated with Tourette disorder. *Neuron* 2017;94:486–499. doi: 10.1016/j.neuron.2017.04.024
14. Eriguchi Y, Kuwabara H, Inai A, Kawakubo Y, Nishimura F, Kakiuchi C, et al. Identification of candidate genes involved in the etiology of sporadic Tourette syndrome by exome sequencing. *Am J Med Genet B Neuropsychiatr Genet* 2017;174:712–723. doi: 10.1002/ajmg.b.32559
15. Nag A, Bochukova EG, Kremeyer B, Campbell DD, Muller H, Valencia-Duarte AV, et al. CNV analysis in Tourette syndrome implicates large genomic rearrangements in *COL8A1* and *NRXN1*. *PLoS One* 2013;8:e59061. doi: 10.1371/journal.pone.0059061
16. Fernandez TV, Sanders SJ, Yurkiewicz IR, Ercan-Sencicek AG, Kim, YS, Fishman DO, et al. Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. *Biological Psychiatry* 2012;71:392–402. doi: 10.1016/j.biopsych.2011.09.034
17. Sundaram SK, Huq AM, Wilson BJ, Chugani, HT. Tourette syndrome is associated with recurrent exonic copy number variants. *Neurology* 2010;74:1583–1590. doi: 10.1212/WNL.0b013e3181e0f147
18. Scharf JM, Yu D, Mathews CA, Neale BM, Stewart SE, Fagerness JA, et al. Genome-wide association study of Tourette’s syndrome. *Mol Psychiatry* 2013;18:721–728. doi: 10.1038/mp.2012.69
19. Alexander J, Potamianou H, Xing J, Deng L, Karagiannidis I, Tsetsos F, et al. Targeted re-sequencing approach of candidate genes implicates rare potentially functional variants in Tourette syndrome etiology. *Front Neurosci* 2016;10:428. doi: 10.3389/fnins.2016.00428
20. Karagiannidis I, Dehning S, Sandor P, Tarnok Z, Rizzo R, Wolanczyk T, et al. Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. *J Med Genet* 2013;50:760–764. doi: 10.1136/jmedgenet-2013-101637
21. Lei J, Deng X, Zhang J, Su L, Xu H, Liang H, et al. Mutation screening of the *HDC* gene in Chinese Han patients with Tourette syndrome. *Am J Med Genet B Neuropsychiatr Genet* 2012;159B:72–76. doi: 10.1002/ajmg.b.32003
22. Wang S, Mandell JD, Kumar Y, Sun N, Morris MT, Arbelaez J, et al. De Novo sequence and copy number variants are strongly associated with Tourette disorder and implicate cell polarity in pathogenesis. *Cell Rep* 2018;24:3441–3454. doi: 10.1016/j.celrep.2018.08.082
23. Aruga J, Yokota N, Mikoshiba K. Human *SLITRK* family genes: genomic organization and expression profiling in normal brain and brain tumor tissue. *Gene* 2003;315:87–94. doi: 10.1016/S0378-1119(03)00715-7
24. Aruga J, Mikoshiba K. Identification and characterization of *Slitrk*, a novel neuronal transmembrane protein family controlling neurite outgrowth. *Mol Cell Neurosci* 2003;24:117–129. doi: 10.1016/S1044-7431(03)00129-5
25. Mah AK. *SLITRK5*, a protein that links striatal deficits to OCD-like behaviours in mice. *Clin Genet* 2010;78:350–352. doi: 10.1111/j.1399-0004.2010.01507.x
26. Shmelkov SV, Hormigo A, Jing D, Proenca CC, Bath KG, Milde T, et al. *Slitrk5* deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. *Nature Med* 2010;16:598–602, 591p following 602. doi: 10.1038/nm.2125
27. Proenca CC, Gao KP, Shmelkov SV, Rafii S, Lee FS. *Slitrks* as emerging candidate genes involved in neuropsychiatric disorders. *Trends Neurosci* 2011;34:143–153. doi: 10.1016/j.tins.2011.01.001
28. Katayama K, Yamada K, Ornathanalai VG, Inoue T, Ota M, Murphy NP, et al. *Slitrk1*-deficient mice display elevated anxiety-like behavior and noradrenergic abnormalities. *Mol Psychiatry* 2010;15:177–184. doi: 10.1038/mp.2008.97
29. Xu M, Li L, Ohtsu H, Pittenger C. Histidine decarboxylase knockout mice, a genetic model of Tourette syndrome, show repetitive grooming after induced fear. *Neurosci Lett* 2015;595:50–53. doi: 10.1016/j.neulet.2015.03.067
30. Baldan LC, Williams KA, Gallezot JD, Pogorelov V, Rapanelli M, Crowley M, et al. Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. *Neuron* 2014;81:77–90. doi: 10.1016/j.neuron.2013.10.052
31. Pittenger C. Histidine decarboxylase knockout mice as a model of the pathophysiology of Tourette syndrome and related conditions. *Handb Exp Pharmacol* 2017;241:189–215. doi: 10.1007/164_2016_127
32. Maia TV, Conceicao VA. Dopaminergic disturbances in Tourette syndrome: an integrative account. *Biol Psychiatry* 2018;84:332–344. doi: 10.1016/j.biopsych.2018.02.1172
33. Worbe Y, Mallet L, Golmard JL, Behar C, Durif F, Jalenques I, et al. Repetitive behaviours in patients with Gilles de la Tourette syndrome: tics, compulsions, or both? *PLoS One* 2010;5:e12959. doi: 10.1371/journal.pone.0012959
34. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. *Nat Biotechnol* 2009;27:182–189. doi: 10.1038/nbt.1523
35. Mi H, Muruganujan A, Huang X, Ebert D, Mills C, Guo X, et al. Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). *Nat Protoc* 2019;14:703–721. doi: 10.1038/s41596-019-0128-8
36. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536(7616):285–291. doi: 10.1038/nature19057
37. de Calbiac H, Dabacan A, Marsan E, Tostivint H, Devienne G, Ishida S, et al. *Depdc5* knockdown causes mTOR-dependent motor hyperactivity in zebrafish. *Ann Clin Transl Neurol* 2018;5:510–523. doi: 10.1002/acn3.542
38. Ozomaro U, Cai G, Kajiwar Y, Yoon S, Makarov V, Delorme R, et al. Characterization of *SLITRK1* variation in obsessive-compulsive disorder. *PLoS One* 2013;8:e70376. doi: 10.1371/journal.pone.0070376

39. Drapeau P, Saint-Amant L, Buss RR, Chong M, McDermid JR, Brustein E. Development of the locomotor network in zebrafish. *Prog Neurobiol* 2002;68:85–111. doi: 10.1016/S0301-0082(02)00075-8
40. Alvarez FA, Rodriguez-Martin I, Gonzalez-Nunez V, Marron Fernandez de Velasco E, Gonzalez Sarmiento R, Rodriguez RE. New kappa opioid receptor from zebrafish *Danio rerio*. *Neurosci Lett* 2006;405:94–99. doi: 10.1016/j.neulet.2006.06.028
41. Sanchez-Simon FM, Arenzana FJ, Rodriguez RE. In vivo effects of morphine on neuronal fate and opioid receptor expression in zebrafish embryos. *Eur J Neurosci* 2010;32:550–559. doi: 10.1111/j.1460-9568.2010.07317.x
42. Loh HH, Smith AP. Molecular characterization of opioid receptors. *Annu Rev Pharmacol Toxicol* 1990;30:123–147. doi: 10.1146/annurev.pa.30.040190.001011
43. Crowley NA, Kash TL. Kappa opioid receptor signaling in the brain: circuitry and implications for treatment. *Prog Neuro Psychopharmacol Biol Psychiatr* 2015;62:51–60. doi: 10.1016/j.pnpbp.2015.01.001
44. Lutz PE, Kieffer BL. The multiple facets of opioid receptor function: implications for addiction. *Curr Opin Neurobiol* 2013;23:473–479. doi: 10.1016/j.conb.2013.02.005
45. Chartoff EH, Mavrikaki M. Sex differences in Kappa Opioid receptor function and their potential impact on addiction. *Front Neurosci* 2015;9:466. doi: 10.3389/fnins.2015.00466
46. Gillman MA, Sandyk R. The endogenous opioid system in Gilles de la Tourette syndrome. *Med Hypotheses* 1986;19:371–378. doi: 10.1016/0306-9877(86)90112-X
47. Kurlan R, Majumdar L, Deeley C, Mudholkar GS, Plumb S, Como PG. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. *Ann Neurol* 1991;30:19–23. doi: 10.1002/ana.410300105
48. Erenberg G, Lederman RJ. Naltrexone and Tourette's syndrome. *Ann Neurol* 1992;31:574. doi: 10.1002/ana.410310520
49. Sarajlija M, Raketic D, Nesic N. Heroin addiction in Serbian patients with Tourette syndrome. *J Psychiatr Pract* 2018;24:424–427. doi: 10.1097/PRA.0000000000000341
50. McConville BJ, Norman AB, Fogelson MH, Erenberg G. Sequential use of opioid antagonists and agonists in Tourette's syndrome. *Lancet* 1994;343:601. doi: 10.1016/S0140-6736(94)91553-9
51. Haber SN, Kowall NW, Vonsattel JP, Bird ED, Richardson EP, Jr. Gilles de la Tourette's syndrome. A postmortem neuropathological and immunohistochemical study. *J Neurol Sci* 1986;75:225–241. doi: 10.1016/0022-510X(86)90097-3
52. Lenington JB, Coppola G, Kataoka-Sasaki Y, Fernandez TV, Palejev D, Li Y, et al. Transcriptome analysis of the human striatum in Tourette syndrome. *Biol Psychiatr* 2016;79:372–382. doi: 10.1016/j.biopsych.2014.07.018
53. Cormier-Dequaire F, Bekadar S, Anheim M, Lebbah S, Pelissolo A, Krack P, et al. Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. *Mov Disord* 2018. doi: 10.1002/mds.27519
54. Erga AH, Dalen I, Ushakova A, Chung J, Tzoulis C, Tysnes OB, et al. Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson's disease. *Front Neurol* 2018;9:109. doi: 10.3389/fneur.2018.00109
55. Wright A, Rickards H, Cavanna AE. Impulse-control disorders in Gilles de la Tourette syndrome. *J Neuropsychiatr Clin Neurosci* 2012;24:16–27. doi: 10.1176/appi.neuropsych.10010013
56. Kivell B, Uzela Z, Sundaramurthy S, Rajamanickam J, Ewald A, Chefer V, et al. Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. *Neuropharmacology* 2014;86:228–240. doi: 10.1016/j.neuropharm.2014.07.016
57. Tejeda HA, Shippenberg TS, Henriksson R. The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. *Cell Mol Life Sci* 2012;69:857–896. doi: 10.1007/s00018-011-0844-x
58. Maia TV, Conceicao VA. The roles of phasic and tonic dopamine in tic learning and expression. *Biol Psychiatr* 2017;82:401–412. doi: 10.1016/j.biopsych.2017.05.025
59. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. *EMBO J* 1998;17:886–897. doi: 10.1093/emboj/17.4.886
60. Filliol D, Ghazizadeh S, Chluba J, Martin M, Matthes HW, Simonin F, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. *Nat Genet* 2000;25:195–200. doi: 10.1038/76061
61. Olmstead MC, Ouagazzal AM, Kieffer BL. Mu and delta opioid receptors oppositely regulate motor impulsivity in the signaled nose poke task. *PLoS One* 2009;4:e4410. doi: 10.1371/journal.pone.0004410
62. Lyu S, DeAndrade MP, Mueller S, Oksche A, Walters AS, Li Y. Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome. *Behav Brain Res* 2019;374:112123. doi: 10.1016/j.bbr.2019.112123
63. Spampinato SM. Overview of genetic analysis of human opioid receptors. *Meth Mol Biol* 2015;1230:3–12. doi: 10.1007/978-1-4939-1708-2_1
64. Kivell BM, Ewald AW, Prisinzano TE. Salvinorin A analogs and other kappa-opioid receptor compounds as treatments for cocaine abuse. *Adv Pharmacol* 2014;69:481–511. doi: 10.1016/B978-0-12-420118-7.00012-3
65. Miranda DM, Wigg K, Feng Y, Sandor P, Barr CL. Association study between Gilles de la Tourette syndrome and two genes in the Robo-Slit pathway located in the chromosome 11q24 linked/associated region. *Am J Med Genet B Neuropsychiatr Genet* 2008;147B:68–72. doi: 10.1002/ajmg.b.30580
66. Torigoe M, Yamauchi K, Tamada A, Matsuda I, Aiba A, Castellani V, et al. Role of neuropilin-2 in the ipsilateral growth of midbrain dopaminergic axons. *Eur J Neurosci* 2013;37:1573–1583. doi: 10.1111/ejn.12190
67. Araki T, Mizutani H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y. Nitric oxide synthase inhibitors cause motor deficits in mice. *Eur Neuropsychopharmacol* 2001;11:125–133. doi: 10.1016/S0924-977X(01)00077-3
68. Sato D, Lionel AC, Leblond CS, Prasad A, Pinto D, Walker S, et al. SHANK1 deletions in males with autism spectrum disorder. *Am J Hum Genet* 2012;90:879–887. doi: 10.1016/S0924-977X(01)00077-3